TY - JOUR
T1 - Effect of losartan and fish oil on plasma IL-6 and mobility in older persons.The ENRGISe pilot randomized clinical trial.
AU - ENRGISE study investigators
AU - Pahor, Marco
AU - Anton, Stephen D.
AU - Beavers, Daniel P.
AU - Cauley, Jane A.
AU - Fielding, Roger A.
AU - Kritchevsky, Stephen B.
AU - Leeuwenburgh, Christiaan
AU - Lewis, Kristina H.
AU - Liu, Christine K.
AU - Lovato, Laura C.
AU - Lu, Jane
AU - Manini, Todd M.
AU - McDermott, Mary M.
AU - Miller, Michael E.
AU - Newman, Anne B.
AU - Radziszewska, Barbara
AU - Stowe, Cynthia L.
AU - Tracy, Russell P.
AU - Walkup, Michael P.
AU - Wu, Samuel S.
AU - Ambrosius, Walter T.
N1 - Funding Information:
The ENRGISE Pilot Study is funded by a National Institutes of Health/ National Institute on Aging Cooperative Agreement U01AG050499. The research is partially supported by the Claude D. Pepper Older Americans Independence Centers at the University of Florida (P30AG028740), Wake Forest University (P30AG021332), Tufts University (P30AG031679), and University of Pittsburgh (P30AG024827). Tufts University is also supported by the Boston Rehabilitation Outcomes Center (R24HD065688-01A1). R.A.F. (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No. 58-1950-0-014. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the U.S. Department of Agriculture. Abbott Laboratories provided funding for the purchase of study drug and matching placebo. The ENRGISE Pilot Study Acknowledgement List is available online as a supplementary file.
Funding Information:
The ENRGISE Pilot Study is funded by a National Institutes of Health/ National Institute on Aging Cooperative Agreement U01AG050499. The research is partially supported by the Claude D. Pepper Older Americans Independence Centers at the University of Florida (P30AG028740), Wake Forest University (P30AG021332), Tufts University (P30AG031679), and University of Pittsburgh (P30AG024827). Tufts University is also supported by the Boston Rehabilitation Outcomes Center (R24HD065688-01A1). R.A.F. (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No. 58-1950-0-014. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the U.S. Department of Agriculture. Abbott Laboratories provided funding for the purchase of study drug and matching placebo. The ENRGISE Pilot Study Acknowledgement List is available online as a supplementary file.
Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Background: Low-grade chronic inflammation, characterized by elevations in plasma Interleukin-6 (IL-6), is an independent risk factor of impaired mobility in older persons. Angiotensin receptor blockers and omega-3 polyunsaturated fatty acids (ω-3) may reduce IL-6 and may potentially improve physical function. To assess the main effects of the angiotensin receptor blocker losartan and ω-3 as fish oil on IL-6 and 400 m walking speed, we conducted the ENRGISE Pilot multicenter randomized clinical trial. Methods: The ENRGISE Pilot enrolled participants between April 2016 and June 2017, who participated for 12 months. Participants were aged ≥70 years with mobility impairment, had IL-6 between 2.5 and 30 pg/mL, and were able to walk 400 m at baseline. Participants were randomized in three strata 2 × 2 factorial to: (i) losartan 50–100 mg/d or placebo (n = 43), (ii) fish oil 1,400–2,800 mg/d or placebo (n = 180), and (iii) with both (n = 66). Results: Two hundred eighty-nine participants were randomized (mean age 78.3 years, 47.4% women, 17.0% black). There was no effect of losartan (difference of means = −0.065 ± 0.116 [SE], 95% confidence interval [CI]: −0.293–0.163, p = .58) or fish oil (−0.020 ± 0.077, 95% CI: −0.171–0.132, p = .80) on the log of IL-6. Similarly, there was no effect of losartan (−0.025 ± 0.026, 95% CI: −0.076–0.026, p = .34) or fish oil (0.010 ± 0.017, 95% CI: −0.025–0.044, p = .58) on walking speed (m/s). Conclusions: These results do not support the use of these interventions to prevent mobility loss in older adults at risk of disability with low-grade chronic inflammation.
AB - Background: Low-grade chronic inflammation, characterized by elevations in plasma Interleukin-6 (IL-6), is an independent risk factor of impaired mobility in older persons. Angiotensin receptor blockers and omega-3 polyunsaturated fatty acids (ω-3) may reduce IL-6 and may potentially improve physical function. To assess the main effects of the angiotensin receptor blocker losartan and ω-3 as fish oil on IL-6 and 400 m walking speed, we conducted the ENRGISE Pilot multicenter randomized clinical trial. Methods: The ENRGISE Pilot enrolled participants between April 2016 and June 2017, who participated for 12 months. Participants were aged ≥70 years with mobility impairment, had IL-6 between 2.5 and 30 pg/mL, and were able to walk 400 m at baseline. Participants were randomized in three strata 2 × 2 factorial to: (i) losartan 50–100 mg/d or placebo (n = 43), (ii) fish oil 1,400–2,800 mg/d or placebo (n = 180), and (iii) with both (n = 66). Results: Two hundred eighty-nine participants were randomized (mean age 78.3 years, 47.4% women, 17.0% black). There was no effect of losartan (difference of means = −0.065 ± 0.116 [SE], 95% confidence interval [CI]: −0.293–0.163, p = .58) or fish oil (−0.020 ± 0.077, 95% CI: −0.171–0.132, p = .80) on the log of IL-6. Similarly, there was no effect of losartan (−0.025 ± 0.026, 95% CI: −0.076–0.026, p = .34) or fish oil (0.010 ± 0.017, 95% CI: −0.025–0.044, p = .58) on walking speed (m/s). Conclusions: These results do not support the use of these interventions to prevent mobility loss in older adults at risk of disability with low-grade chronic inflammation.
UR - http://www.scopus.com/inward/record.url?scp=85072508706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072508706&partnerID=8YFLogxK
U2 - 10.1093/gerona/gly277
DO - 10.1093/gerona/gly277
M3 - Article
C2 - 30541065
AN - SCOPUS:85072508706
SN - 1079-5006
VL - 74
SP - 1612
EP - 1619
JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
IS - 10
ER -